Exactech Knee, Hip & Ankle Implant Recall Lawsuit: MDL 3044, Bankruptcy, and How to File a Claim in 2026

What Happened with Exactech Implants — and Why This Still Matters in 2026

In early 2022, Exactech Inc., a Florida-based orthopedic device manufacturer, recalled hundreds of thousands of polyethylene inserts used in knee, hip, and ankle replacement systems. The reason: the vacuum-sealed packaging that was supposed to protect the polyethylene from oxygen was out of specification. The consequence: the plastic bearing component was already oxidizing on the shelf, before it was ever implanted.

Oxidized polyethylene wears out faster. Joints that should last 15 to 20 years were failing within five years — sometimes sooner. Patients experienced persistent pain, joint instability, and osteolysis (bone loss around the implant). Many had no choice but to undergo revision surgery, a more complex and risky procedure than the original replacement.

As of May 2026, the litigation is at a critical juncture. Exactech filed for Chapter 11 bankruptcy in October 2024. The automatic stay halted active litigation in MDL 3044. Claimants must now navigate the bankruptcy process to seek recovery. This guide explains what that means, who qualifies, and what steps to take now.

This article is for informational purposes only and does not constitute legal advice.

---

Which Exactech Devices Are Affected?

The recall covers three joint systems, each with separate timelines.

Joint	Models	Recall Date	Approximate Units	Scope
Knee	Optetrak, Optetrak Logic, Truliant	February 2022	~147,000	Manufactured after 2004
Ankle	Vantage	February 2022	~1,500
Hip	Novation, Acumatch, MCS	June 2021 (initial); August 2022 (expanded)	40,000+

Understanding the knee model timeline:

• Optetrak was launched in 1994 and became Exactech’s highest-volume knee product. The recall covers devices manufactured after 2004, making this the largest portion of affected units.
• Optetrak Logic launched in 2009 as an updated version. Subject to the same packaging defect.
• Truliant launched in 2017 — the most recent design, but subject to the same defective packaging from its introduction.

If you are unsure whether your implant is affected, visit recall.exac.com and enter your device serial number. You can also request your surgical implant record — a sticker placed in your chart at time of surgery containing the product name, lot number, and serial number.

---

The Failure Mechanism: Oxidized Polyethylene

Polyethylene inserts serve as the bearing surface between the metal components in a joint replacement. They absorb shock, reduce friction, and allow smooth movement. The material used — ultra-high molecular weight polyethylene (UHMWPE) — is designed to withstand millions of loading cycles over many years. But its durability depends critically on maintaining its molecular structure intact at the time of implantation.

Oxygen is the enemy. When UHMWPE is exposed to oxygen, oxidative degradation begins. The material becomes brittle, loses its mechanical properties, and wears at a rate far exceeding what is expected of a properly manufactured and stored device.

Exactech’s packaging was supposed to prevent this. The vacuum-sealed bags were designed to exclude oxygen during storage and distribution. But the bags used on affected devices were out of specification — they allowed oxygen to permeate. By the time a surgeon opened the package in the operating room, the polyethylene had already begun to oxidize.

The clinical consequence:

1. Accelerated polyethylene wear produces submicron debris particles
2. The body’s immune response to debris causes osteolysis — the immune system essentially dissolves surrounding bone
3. The implant loses its fixation as bone support erodes
4. Result: mechanical loosening, pain, instability, and eventual need for revision surgery

This defect was not visible to the operating surgeon. Nothing in the surgical record at time of implantation would flag a compromised device. Patients and surgeons were unaware. The problem typically manifested years later, when patients began noticing unexplained pain or instability.

---

MDL 3044: The Federal Litigation Hub

Exactech lawsuits from across the country were consolidated into a single multidistrict litigation (MDL) in October 2022.

MDL 3044 at a Glance:

• Full title: In re: Exactech Polyethylene Orthopedic Products Liability Litigation
• MDL No.: 3044 (verified)
• Court: U.S. District Court, Eastern District of New York (Brooklyn)
• Presiding judge: Hon. Nicholas G. Garaufis
• Established: October 2022
• Federal cases pending: Approximately 1,800–1,838 at time of bankruptcy filing
• Florida state court cases: 80+ additional

MDL consolidation serves efficiency. Discovery (depositions, document production, expert witness reports) happens once, benefiting all plaintiffs. Bellwether trials — test cases using representative facts — help parties assess settlement value. In MDL 3044, bellwether trials were originally scheduled for July 2025. The October 2024 bankruptcy filing disrupted that schedule.

---

Exactech’s Chapter 11 Bankruptcy: What It Means for Patients

On or about October 2024, Exactech Inc. filed for Chapter 11 bankruptcy protection. The company cited mounting litigation costs — estimated at approximately $20 million by late 2024 — as a primary driver.

Chapter 11 is a reorganization, not a liquidation. The company continues operating (or winding down) under court supervision while developing a plan to address debts, including litigation claims. Johnson & Johnson employed a similar strategy in its talc litigation — a controversial tactic that has faced legal challenges but remains available to defendants under the bankruptcy code.

What the bankruptcy means for MDL 3044 plaintiffs:

The automatic stay immediately suspended all active litigation against Exactech in MDL 3044 and state courts. New lawsuits cannot be filed against the company while the stay is in effect. Plaintiffs who have not yet filed claims must now participate in the bankruptcy process.

The bankruptcy trustee’s new lawsuit against TPG:

The bankruptcy trustee filed a separate legal action against TPG, the private equity firm that previously owned Exactech, and related parties. Details of that lawsuit remain sealed as of the latest available information. If successful, this action could substantially increase the pool of funds available to injured patients.

Status conferences: A hearing was held January 9, 2025. The court required joint status reports every 90 days. Other case deadlines remain adjourned pending further court guidance on the bankruptcy’s impact.

---

Who Qualifies to File a Claim?

You may have a valid claim if:

• You received a knee, hip, or ankle replacement using an Exactech device covered by the recall
• AND you have experienced one or more of the following:
  • Premature joint failure (typically within 10 years of surgery, often within 5)
  • Persistent unexplained pain, instability, or reduced range of motion
  • X-ray or imaging evidence of osteolysis, loosening, or implant migration
  • Revision surgery already completed
  • Physician recommendation for revision surgery

A note on surgery timing:

The knee recall covers devices manufactured after 2004. If your Optetrak, Optetrak Logic, or Truliant knee replacement occurred after 2004 and you are experiencing symptoms, the device may be within the recall scope.

Even if you have no symptoms, if your device falls within the recall, AAOS guidelines support regular clinical monitoring — typically annual visits and periodic imaging — to detect subclinical failure before it becomes an emergency.

---

Building Your Case: Evidence That Matters

Surgical records:

• Operative report from the original joint replacement surgery
• Implant sticker or card (product name, lot number, serial number)
• Discharge summary

Imaging:

• Pre-operative and post-operative X-rays
• Any subsequent imaging showing osteolysis, loosening, or component migration
• MRI or CT if obtained

Follow-up records:

• Any physician notes documenting pain, instability, or concern about device performance
• Revision surgery records (including intraoperative findings — look for notes mentioning oxidized polyethylene, debris, or early wear)

Economic damages:

• Medical bills for revision surgery and related care
• Out-of-pocket costs (transportation, home care, physical therapy)
• Lost wages documentation if applicable

Why MAUDE matters: The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database collects adverse event reports from manufacturers, device user facilities, and patients. Plaintiff attorneys use MAUDE data to establish when Exactech first received reports of premature failures — key to arguing the company knew or should have known about the defect and acted with inadequate urgency.

Daubert considerations: In federal MDL proceedings, expert testimony is subject to Daubert scrutiny — the court acts as gatekeeper to ensure expert opinions are based on reliable methodology. Plaintiff experts in MDL 3044 have used materials science analysis and clinical outcomes data to support causation arguments linking oxidized polyethylene to early device failure.

---

Statute of Limitations by State

State product liability statutes of limitations determine how long you have to file a claim. The automatic stay in bankruptcy does not necessarily toll (pause) state statutes of limitations in the same way, and the proof-of-claim deadline in the bankruptcy has its own timeline.

General reference (verify with an attorney for your state):

State	Product Liability SOL	Discovery Rule?
California	2 years	Yes
Texas	2 years	Limited
New York	3 years	Yes
Florida	2 years (shortened 2023)	Yes
Illinois	2 years	Yes
Georgia	2 years	Yes
New Jersey	2 years	Yes
Washington	3 years	Yes
Ohio	2 years	Yes
Pennsylvania	2 years	Yes

The discovery rule means the clock typically starts when you knew or should have known of the harm — often interpreted as when symptoms appeared or when the recall was announced (February 2022 for knee/ankle; June 2021/August 2022 for hip). However, bankruptcy complicates this analysis. Speak with an attorney without delay.

---

Manufacturer vs. Physician Liability

Exactech is the primary defendant. It designed, manufactured, and distributed the defective devices. Product liability claims against a manufacturer may proceed under theories of:

• Manufacturing defect — the specific devices produced had a physical flaw (out-of-spec packaging)
• Design defect — the packaging specification itself was inadequate
• Failure to warn — Exactech may have known of packaging problems before initiating the recall

When a physician or hospital might also be liable:

If a physician continued implanting recalled devices after the February 2022 recall announcement without informing patients — or failed to arrange timely follow-up monitoring for at-risk patients — a separate medical negligence claim may exist. This is a fact-specific analysis: a physician who was unaware of the recall at the time, or who appropriately notified patients, is unlikely to face negligence exposure for the underlying defect.

---

Two Patient Scenarios

Scenario A: Revision surgery completed in 2024

A 67-year-old retired teacher in Ohio received bilateral Optetrak knee replacements in 2011 and 2014. By 2023, she experienced significant pain and instability in her right knee. Imaging showed osteolysis and loosening. She underwent revision surgery in early 2024. The surgical notes document oxidized polyethylene debris and significant bone loss.

Her attorney would use the revision surgery records, imaging, and intraoperative findings to establish causation. Ohio’s two-year product liability SOL means she has until approximately early 2026 to file — but the bankruptcy automatic stay currently prevents court filing, making proof-of-claim filing through the bankruptcy the correct path.

Scenario B: Recall-period device, no revision yet

A 58-year-old man in Texas received a Truliant knee replacement in 2019. After the 2022 recall, his orthopedic surgeon ordered follow-up X-rays annually. A 2025 X-ray revealed early-stage osteolysis. No revision surgery has been recommended yet.

He still has a viable claim. Osteolysis documented by imaging represents measurable harm from the defective device. An expert opinion that revision surgery will be required in the future supports recovery for anticipated costs and damages. He should file a proof of claim through the bankruptcy before the deadline.

---

Compensation Estimates and Fee Structure

Pre-bankruptcy settlement projections (for context):

Before Exactech’s Chapter 11 filing, attorneys handling MDL 3044 cases estimated settlement values for knee revision cases at approximately $130,000 to $190,000. Ankle cases involving Vantage were projected higher, reflecting the relative rarity and severity of ankle revision surgery.

These figures were projections from before the bankruptcy. In a Chapter 11 resolution, the actual amount each claimant receives depends on:

• Total assets available for distribution
• Number of filed claims
• Outcome of the trustee’s action against TPG
• The bankruptcy court’s reorganization plan approval

Attorney fee structure:

Mass tort and product liability attorneys universally work on contingency:

• Pre-trial resolution: approximately 33%
• Post-filing settlement: 33%–36%
• Trial: up to 40%

No upfront fees. If there is no recovery, you pay nothing. Initial consultations are free.

---

The Revision Surgery Experience — What Patients Should Understand

Revision joint replacement surgery is fundamentally different from a primary replacement. Surgeons must remove the failed components, address bone loss caused by osteolysis, and implant revision-specific components designed for compromised anatomy. The American Academy of Orthopaedic Surgeons (AAOS) describes revision surgery as significantly more complex due to scarring, bone loss, and the need to restore joint line and stability.

What revision surgery involves:

For knee revisions, surgeons typically must address:

• Removal of well-fixed metal components (which may require specialized extraction tools if cement or bone ingrowth is present)
• Debridement of oxidized polyethylene debris and inflammatory tissue
• Assessment and treatment of osteolytic bone defects — sometimes requiring bone grafts or metal augments
• Implantation of constrained or semi-constrained revision components that compensate for ligament laxity caused by long-standing loosening

For hip revisions, the process similarly involves:

• Cup and stem extraction
• Bone graft to fill acetabular or femoral defects from osteolysis
• Extended recovery — often longer and more demanding than the original surgery

Patients who underwent revision surgery for Exactech device failures frequently report significantly longer rehabilitation timelines and outcomes that may not fully match the initial replacement’s performance. These functional limitations form part of the compensable damages in the litigation.

---

How the Mass Tort Process Works — From Case Filing to Bankruptcy Claim

Understanding the process helps patients make informed decisions. Before Exactech’s bankruptcy, the typical mass tort pathway looked like this:

1. Retain attorney — attorney evaluates claim, gathers records
2. File complaint — either in MDL directly or in home-state federal court for transfer to EDNY
3. Discovery phase — document production, depositions (Exactech employees, expert witnesses)
4. Daubert hearings — court rules on admissibility of expert testimony on causation
5. Bellwether trials — small group of representative cases tried to verdict; results inform settlement value
6. Global settlement negotiations — parties agree on aggregate settlement fund and claim criteria

The bankruptcy short-circuits steps 3–6. Instead:

1. Retain attorney — still critical for navigating bankruptcy claims
2. File proof of claim with the bankruptcy court by the claims bar date
3. Claims assessment — bankruptcy trustee and court evaluate the pool of claims
4. Reorganization plan — company or trustee proposes how assets are distributed among creditors (which includes injury claimants)
5. Distribution — eligible claimants receive their share based on the approved plan

The key variable is the total pool of assets. If the bankruptcy trustee’s lawsuit against TPG succeeds, it could significantly increase what is available for distribution. Attorneys will use this as leverage throughout the process.

---

Monitoring Your Implant — What AAOS Guidelines Recommend

Whether or not you have symptoms, the AAOS and orthopedic surgeon organizations recommend that patients with recalled Exactech implants undergo regular clinical monitoring. The standard approach includes:

• Annual clinical visit with your orthopedic surgeon
• Periodic standing X-rays of the affected joint (weight-bearing AP and lateral views) to assess for component position, polyethylene wear, and osteolysis
• Patient-reported outcome measures — standardized questionnaires (e.g., KOOS for knee, HOOS for hip) to track functional decline over time
• Low threshold for advanced imaging — if X-rays show any bone changes around the implant, MRI or CT (with metal artifact reduction protocols) may be warranted

Document every clinical encounter related to your implant. If your surgeon has not mentioned the recall or recommended monitoring, bring it up proactively. Your surgical implant record — which the hospital should have — will tell you exactly what product was used.

---

Exactech’s Corporate History and Ownership — Why TPG Matters

Understanding Exactech’s ownership history is relevant because it explains why the bankruptcy trustee filed suit against TPG.

Exactech was founded in 1988 by orthopedic surgeon Gary Miller and engineer Bill Petty in Gainesville, Florida. The company grew to become a significant player in the mid-market orthopedic device space. In 2018, TPG Capital — a major private equity firm — acquired Exactech for approximately $737 million in an all-cash transaction.

The recall of defective polyethylene packaging was announced in 2022 — four years into TPG’s ownership. Critics of private equity ownership in medical device companies argue that financial pressure to reduce costs can lead to manufacturing shortcuts or delayed quality control responses. The bankruptcy trustee’s sealed lawsuit against TPG likely centers on questions of corporate governance, resource allocation during the ownership period, and whether the packaging defect’s scope was known and not adequately addressed.

This is not merely legal background. If the trustee’s action results in a significant judgment or settlement with TPG, the funds available to injured patients increase substantially. Patients and their attorneys should monitor this parallel proceeding closely.

---

Frequently Confused Issues — Clarifying Common Misconceptions

“I had my surgery years ago and feel fine. Does the recall apply to me?”

Yes, it may. Polyethylene oxidation is a progressive process. Some patients may not experience symptoms for many years. Subclinical osteolysis — bone loss that has not yet caused pain — can be detected on imaging before the patient notices anything wrong. Annual monitoring is recommended even for currently asymptomatic patients with recalled devices.

“My doctor said my implant is fine.”

A physician’s clinical assessment is valuable, but it should be supported by imaging. A physical exam alone cannot rule out osteolysis. Request weight-bearing X-rays and ask specifically whether your implant is within the recall scope. If it is, insist on documented follow-up.

“The recall notice said no action is required.”

Some recall communications were directed at healthcare facilities and were phrased to minimize alarm. Patients who have already had devices implanted cannot “un-implant” a recalled device without revision surgery. The “no action” language referred to the fact that healthy-functioning devices should not be prophylactically removed — not that patients have no legal rights.

“I used Medicare / VA insurance. I cannot sue.”

Medicare and VA patients have product liability rights identical to privately insured patients. However, these government payers may hold subrogation rights — the right to seek reimbursement from any settlement for costs they covered. An attorney can calculate and address these obligations.

---

What to Do Right Now

1. Confirm your implant. Go to recall.exac.com. Enter your serial number. If you don’t have it, call the hospital where you had surgery and request your implant sticker record.

2. Gather your medical records. Request operative reports, discharge summaries, and imaging from every provider involved in your joint replacement care.

3. Schedule a clinical evaluation. If you have not had recent X-rays, ask your orthopedic surgeon to order imaging to assess your implant’s current condition.

4. Document your symptoms. Keep a journal: when pain started, what activities it limits, any falls or instability incidents.

5. Consult a mass tort attorney immediately. The bankruptcy proof-of-claim deadline is time-sensitive and separate from state SOL. Missing it can eliminate your recovery. Initial consultations are free.

6. Do not sign anything from Exactech or its insurers without attorney review.

7. If your state SOL is approaching, tell your attorney immediately — even though the automatic stay prevents new court filings, your attorney needs to protect your rights through the bankruptcy claims process before any applicable deadlines expire.

---

Comparing Exactech to Other Major Orthopedic Device Recalls

Understanding where the Exactech litigation fits relative to other major orthopedic mass torts helps set expectations.

DePuy ASR Hip (Johnson & Johnson) — recalled 2010: The DePuy ASR metal-on-metal hip recall resulted in one of the largest medical device settlements in history. J&J ultimately paid over $4 billion across multiple settlement tranches to resolve tens of thousands of claims. The ASR recall involved a different failure mechanism (metal ions released by metal-on-metal articulation causing pseudotumor and metallosis) but shares with Exactech the pattern of premature device failure requiring revision surgery. This litigation served as a template for how bellwether trials, global settlement funds, and claims resolution programs are structured in orthopedic device mass torts.

Biomet Metal-on-Metal Hip — settled 2014: Biomet agreed to a $56 million settlement fund in 2014 for its M2a metal-on-metal hip implants, a fraction of what DePuy paid. The difference reflected the smaller scale of affected patients and the extent of individual injury documentation.

What this means for Exactech: The key difference with Exactech is the Chapter 11 bankruptcy filing. Unlike DePuy (J&J) and Biomet, Exactech does not have the balance sheet to fund a large voluntary settlement. The outcome for patients depends heavily on (a) the total assets the bankruptcy estate can assemble, (b) the trustee’s action against TPG, and (c) whether the bankruptcy court approves a fair reorganization plan. Attorneys with mass tort experience will use the DePuy and other precedents to argue for adequate compensation standards in the bankruptcy plan negotiations.

---

Understanding Your Rights Under FDCA and State Law

The Federal Food, Drug, and Cosmetic Act (FDCA) governs the FDA’s oversight of medical devices. Exactech’s polyethylene inserts were cleared under the FDA’s 510(k) process — a pathway that allows devices to be marketed without clinical trials if they are substantially equivalent to a previously cleared device. Critics argue this pathway can allow safety issues to go undetected.

Under federal law (Medtronic v. Lohr and Riegel v. Medtronic), the preemption landscape differs by device class. Class II devices cleared through 510(k) generally do not trigger complete federal preemption of state tort claims. This means patients can pursue state law product liability claims — failure to warn, manufacturing defect, design defect — without being blocked by federal preemption arguments.

State law theories in Exactech cases:

• Strict products liability (manufacturing defect): The specific packaging of a given lot failed to meet specification — the device as actually manufactured deviated from its intended design
• Strict products liability (design defect): If the vacuum-seal specification itself was inherently inadequate, this broader design defect theory may apply
• Negligence: Exactech owed a duty of care in manufacture and quality control; breach of that duty caused patient harm
• Breach of implied warranty of merchantability: The device was not fit for its ordinary purpose
• Fraud/misrepresentation: If Exactech had data suggesting packaging failures prior to recall and continued marketing the devices, fraud claims may be available in some states

In the bankruptcy context, the legal theories still matter — they determine the strength of each claimant’s position and influence how claims are valued in the reorganization plan.

---

Monitoring Future Developments in the Exactech Bankruptcy

The situation is actively evolving. Key milestones to track:

1. Claims bar date announcement — the bankruptcy court will set a deadline by which all injury claims must be filed. This is different from state statutes of limitations and may be the most urgent deadline for many patients.

2. Disclosure statement and reorganization plan — Exactech or the trustee will file a proposed plan explaining how assets will be distributed. Creditors, including injury claimants, will have an opportunity to object or vote.

3. TPG lawsuit outcome — if the trustee’s sealed case against TPG advances toward resolution, it will signal the potential for significantly larger recovery.

4. MDL 3044 lift-stay motions — plaintiffs’ attorneys may seek to lift the automatic stay for certain purposes (e.g., to preserve statute of limitations rights in specific states). Monitoring court orders in EDNY will provide guidance.

5. Appeals — contested issues in the bankruptcy may be appealed, extending the timeline.

Sign up for free case-status alerts through PACER (Public Access to Court Electronic Records) using the MDL 3044 case number to receive email notifications when new documents are filed.

---

Related Medical Device and Injury Litigation

• Paragard IUD Breakage Lawsuit 2026
• Hair Relaxer Cancer Lawsuit MDL 2026
• Medical Malpractice and Birth Injury Lawsuits 2026
• Personal Injury Lawyer Fee Structures 2026
• Mesothelioma Lawyer and Settlement Guide 2026
• Hernia Mesh Lawsuit Update 2026

---

This article is for informational purposes only and does not constitute legal advice. Laws vary by state and your individual circumstances. Consult a licensed attorney for advice specific to your situation. Information current as of May 2026; the bankruptcy process is ongoing and details may change.